Piper Sandler upgraded Tempus AI to Overweight from Neutral. The firm raised its price target for the stock to $76 from $56.
Analysts highlighted the pending acquisition of Personalis and its tumor-informed MRD platform as a primary growth driver. A recent positive clinical trial readout further enhanced the strategic value of the Personalis deal.
The upgrade also cited recent FDA approval for the xT CDx tumor-only test as a crucial step toward unified pricing. Separately, Canaccord Genuity reiterated a Buy rating on the stock with an $80 price target.
Canaccord noted that broad strategic interest in Personalis validates the acquisition's value. The firm also identified potential for further synergies following the transaction.